EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 667-674

  Boye, K ^a   Nesland, J M ^a,b   Sandstad, B ^a   Haugland Haugen, M ^a   Maelandsmo G M ^a,c   Flatmark, K ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

colorectal cancer; EMMPRIN; prognostic biomarker; S100A4

Indexed keywords

CALVASCULIN; CD147 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; TUMOR CELL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864868843     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.293     Document Type: Article

References (41)

1. Bao W, Min D, Twigg SM, Shackel NA, Warner FJ, Yue DK, McLennan SV (2010) Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications. Am J Physiol Cell Physiol 299: C1212-C1219
2. Berge G, Pettersen S, Grotterød I, Bettum IJ, Boye K, Mælandsmo GM (2011) Osteopontin-an important downstream effector of S100A4-mediated invasion and metastasis. Int J Cancer 129: 780-790
3. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434-439
4. Bjørnland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O, Mælandsmo GM (1999) S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 59: 4702-4708
5. Boe S, Longva AS, Hovig E (2007) Photochemically induced gene silencing using small interfering RNA molecules in combination with lipid carriers. Oligonucleotides 17: 166-173
6. Boye K, Grotterød I, Aasheim HC, Hovig E, Mælandsmo GM (2008) Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J Cancer 123: 1301-1310
7. Boye K, Mælandsmo GM (2010) S100A4 and metastasis: a small actor playing many roles. Am J Pathol 176: 528-535
8. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010) Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer 46: 2919-2925
9. Buergy D, Fuchs T, Kambakamba P, Mudduluru G, Maurer G, Post S, Tang Y, Nakada MT, Yan L, Allgayer H (2009) Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer. Cancer 115: 4667-4678
10. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010) Colorectal cancer. Lancet 375: 1030-1047
11. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI (2004) Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10: 8229-8234
12. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174
13. Flatmark K, Bjørnland K, Johannessen HO, Hegstad E, Rosales R, Harklau L, Solhaug JH, Faye RS, Soreide O, Fodstad O (2002) Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 8: 444-449
14. Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Harklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad O (2011) Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer 104: 1434-1439
15. Flatmark K, Mælandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad O, Paus E (2004) Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol 25: 31-40
16. Grotterød I, Mælandsmo GM, Boye K (2010) Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB. BMC Cancer 10: 241
17. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005) Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 1197-1205
18. Han ZD, He HC, Bi XC, Qin WJ, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Zhu G, Chen ZN, Zhong WD (2010) Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res 160: 260-267
19. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, Rahkonen O, Laato M (2007) Prognostic significance of matrix metalloproteinases-1,-2,-7 and-13 and tissue inhibitors of metalloproteinases-1,-2,-3 and-4 in colorectal cancer. Int J Cancer 121: 714-723
20. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012) B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer; e-pub ahead of print 2 April 2012; doi:10.1002/ijc.27566
21. Jin JS, Wu CY, Lin YF, Wang JY, Yu CP, Sheu LF, Chiang H, Tsai WC, Lee WH (2006) Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Dis Markers 22: 309-316
22. Jung EJ, Lee JH, Min BW, Kim YS, Choi JS (2011) Clinicopathologic significance of fascin, extracellular matrix metalloproteinase inducer, and ezrin expressions in colorectal adenocarcinoma. Indian J Pathol Microbiol 54: 32-36
23. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmuller G (2002) Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20: 387-392
24. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK, Barlow JF for the North Central Cancer Treatment Group and the Mayo Clinic (1989) Surgical adjuvant therapy of largebowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7: 1447-1456
25. Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, Zhang Y, Liao CG, Bian HJ, Jiang JL, Yang XM, Li XY, Fan CM, Zhu P, Fu L, Chen ZN (2009) HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 54: 677-687
26. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358
27. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461-462
28. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425
29. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Janicke F, Sauter G, Pantel K (2004) Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10: 3422-3428
30. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119: 1800-1810
31. Saleem M, Kweon MH, Johnson JJ, Adhami VM, Elcheva I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-Shaw S, Spiegelman VS, Setaluri V, Mukhtar H (2006) S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA 103: 14825-14830
32. Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E, Lukanidin E, Ambartsumian N (2004) Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 23: 5487-5495
33. Sidhu SS, Nawroth R, Retz M, Lemjabbar-Alaoui H, Dasari V, Basbaum C (2010) EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene 29: 4145-4156
34. Sienel W, Polzer B, Elshawi K, Lindner M, Morresi-Hauf A, Vay C, Eder F, Passlick B, Klein CA (2008) Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol 21: 1130-1138
35. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH (2006) The metastasis-associated gene S100A4 is a novel target of betacatenin/T-cell factor signaling in colon cancer. Gastroenterology 131: 1486-1500
36. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65: 3193-3199
37. Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-292
38. van der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN (2009) Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol 101: 259-269
39. Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93: 199-204
40. Zheng HC, Wang W, Xu XY, Xia P, Yu M, Sugiyama T, Takano Y (2011) Up-regulated EMMPRIN/CD147 protein expression might play a role in colorectal carcinogenesis and its subsequent progression without an alteration of its glycosylation and mRNA level. J Cancer Res Clin Oncol 137: 585-596
41. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, Foda HD, Tompkins DC, Toole BP (2001) Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158: 1921-1928